Can women take Viagra?
The other 6 in sildenafil and 3 in the placebo groups were lost to follow-up.
Cited by (61)
Participants were seen at baseline and at weeks 2, 4, and 8 (or last visit) for assessments that included measures of change from baseline to weeks 2, 4, and 8 (or last visit). The Clinical Global Impression scale is a clinician-rated severity improvement scale derived from a review of the diary and discussion with the patient for measuring sexual function with changes measured from baseline to weeks 2, 4, and 8 (final or last visit) with anchored scores from 1 (normal) to 7 (most extreme sexual dysfunction).26 The sexual function questionnaire is a 34-item, multidimensional, patient-rated, self-report, outcome measure of female sexual function developed and validated in English and several other languages.27 It quantifies sexual function in 7 functional domains (desire, arousal-sensation, arousal-lubrication, orgasm, enjoyment, pain, partner) of the female sexual response cycle to detect change in and distinguish between the presence and absence of female sexual dysfunction consistent with the DSM-IV diagnostic criteria. Anchored 5- or 7-point individual item response scales are scored, ascending or descending, from 0 or higher to 6 or lower (most are 1 to 5) with the higher scores indicating better sexual function. The 7 domain composite–section scores add to a total score range of 30 to 167: sexual desire (range, 5-31), arousal-sensation (range, 4-20), arousal-lubrication (range, 2-10), orgasm (range, 3-15), pain (range, 2-15), partner (range, 2-10), and enjoyment (range, 6-30). Responses of not applicable were entered as missing.
Prevalence of and recent developments in female sexual dysfunction
To provide concurrent validity, we used the Arizona Sexual Experience and the University of New Mexico Sexual Function Inventory scales. Both are shorter and well-established instruments that have been validated in patients with psychiatric disorders. They weight sexual function domains equally with different wording and anchors at administration. The Arizona scale is a 5-item, patient-rated questionnaire that quantifies sexual drive, arousal (subjective excitement), lubrication (physiological excitement), ability to reach orgasm, and orgasm satisfaction using anchored 6-point scales from 1 (good function) to 6 (poor function) for each item with a total score ranging from 5 to 30 (higher scores indicate greater sexual dysfunction).28 The University of New Mexico scale29 is a 5-item, clinician-rated—for this study—questionnaire derived from and similar to the Arizona28 and the Massachusetts General Hospital-Sexual Function questionnaires.30 It uses anchored 6-point scales from 1 (good function) to 6 (poor function) for each item (desire, sexual arousal, ability to achieve lubrication, ability to achieve orgasm, and overall satisfaction) to quantify presence and changes in sexual dysfunction independent of disease state or medication (lower scores indicate better or improvement in sexual function). The 17-item Hamilton depression rating23 was administered at baseline and at weeks 2, 4, and 8 (or last visit) to monitor depression severity to ensure that the severity of depression had not changed to be more than 10 (relapse of major depression excluded study continuation). No discontinuations for intolerable or serious adverse events were reported (Figure).
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Kamagra Polo | 100mg | 84 + 4 Pills | 244.49€ 232.85€ | |
| Viagra Generic | 200mg | 60 + 4 Pills | 125.19€ 119.23€ | |
| Kamagra | 100mg | 84 + 6 Pills | 264.44€ 251.85€ | |
| Kamagra Soft Tabs | 100mg | 272 + 12 Pills | 593.42€ 565.16€ | |
| Viagra Generic | 150mg | 360 + 10 Pills | 423.48€ 403.31€ | |
| Viagra Generic | 25mg | 20 Pills | 37.74€ 35.94€ | |
| Kamagra Polo | 100mg | 272 + 12 Pills | 622.94€ 593.28€ | |
| Viagra Generic | 100mg | 120 + 6 Pills | 149.50€ 142.38€ | |
| Kamagra | 100mg | 180 + 6 Pills | 436.79€ 415.99€ | |
| Viagra Generic | 100mg | 360 + 10 Pills | 330.21€ 314.49€ | |
| Viagra Generic | 25mg | 30 + 4 Pills | 47.97€ 45.69€ | |
| Viagra Generic | 25mg | 180 + 6 Pills | 154.93€ 147.55€ | |
| Viagra Generic | 200mg | 20 Pills | 61.69€ 58.75€ | |
| Kamagra | 100mg | 60 + 4 Pills | 201.34€ 191.75€ | |
| Kamagra Polo | 100mg | 120 + 6 Pills | 327.15€ 311.57€ | |
| Kamagra Soft Tabs | 100mg | 60 + 4 Pills | 180.59€ 171.99€ |
As determined by the inclusion criteria, the prevalence of sexual problems was high and the mean (SD) number of problems reported was 3.0
Materials and Methods:
The change in sexual functioning by Clinical Global Impression sexual function score and all other questionnaires from baseline to each patient's own end point were the dependent measures of efficacy. A repeated measures analysis of variance was used to determine differences between placebo and sildenafil in the change from baseline to end point for the measures of efficacy and depression severity (time × group interaction). In addition, exact nonparametric methods were applied to the efficacy measures to substantiate results that rely on distributional assumptions. Findings were also confirmed with analysis of covariance and Wilcoxon rank sum tests for primary analyses. All statistical tests were 2-sided, and all hypotheses were evaluated at the 5% significance level.
Full Text Sources
The F test of the overall hypothesis test was first conducted before multiple comparisons analyses. Sample-size calculations were based on detecting a difference in full response rates at 8 weeks, assuming a response rate of 70% for sildenafil and 35% for placebo. Thus, a sample size of 82 evaluable patients (41 per group) was expected to detect a significant difference with 90% power for a type I error rate of α = .05 between sildenafil and placebo (2-sided). Assuming 20% attrition, 100 patients were planned to be randomized and 98 patients were entered. The sample size determination assumed no interactions of treatment with site or antidepressant. (0.7) for the sildenafil group and 2.8 (0.7) the placebo group (P = .21), with 95.8% of women reporting more than 1 complaint.
- Research shows mixed results on sildenafil's benefits for women.
- It may improve sexual satisfaction in some women.
- Not recommended for women with cardiovascular conditions.
- Using sildenafil without medical advice is risky.
They reported disturbances in desire (87.8%), subjective arousal (80.6%), lubrication (79.6%), orgasm delay
European Journal of Obstetrics & Gynecology and Reproductive Biology
There were no statistically significant differences between baseline demographics in the assigned treatment groups (Table 1). Systematic review for any protocol deviations in patient enrollment was undertaken before unbinding. The 98 randomized women constituted the last-observation-carried-forward analysis. Seventy-six women (77.6%) completed the study: with 75.5% (37 of 49) in the placebo group and 79.6% (39 of 49) in the sildenafil group and constituted the completer population. Nine women in the placebo group and 4 in the sildenafil group discontinued prematurely for lack of efficacy. (98.7%), and other difficulties (23.6%), which included anorgasmia, lack of pleasure, and pain.
Methods and Objectives
The primary analysis was according to assignment at randomization. In addition to determination of this narrow measure of efficacy based on all randomized patients and imputing the worst rank scores for early exclusions due to protocol violations before and without taking the trial drug, there was a general efficacy analysis for all protocol-treated patients and all trial completers. Adjusted means women sildenafil (SDs) were determined and reported. Where applicable, 95% confidence intervals (CIs) are provided. Analyses were performed with SAS version 9.1.3 (SAS Institute Inc, Cary, North Carolina).
Physiology of female sexual function: Animal models
One hundred women (Figure) of the 145 screened met eligibility requirements. Among the most frequent causes for exclusion were ineligible protocol criteria (ie, lack of acceptable and verifiable form of contraception, perimenopausal with irregular cycles or amenorrhea, non-SRI sexual dysfunction augmentation, switching antidepressant agent, other treatments for sexual dysfunction), and other miscellaneous reasons (partner issues, abnormal Papanicolaou test results, medical comorbidity, excessive alcohol use, or relationship or partner problems). Two eligible participants were withdrawn after they were screened but before they were randomized. One patient had a change in antidepressant dose made by her primary care physician. The other patient withdrew due to her partner's serious injuries. Prior to study entry, the women self-reported a mean (SD) of 6.0 (5.2) sexual attempts per month, of which 1.4 (2.0), or 29.6% (34.9%), were considered successful.
- Sildenafil is being studied for female sexual dysfunction.
- It may improve blood flow to vaginal tissues.
- Not officially approved for women in many countries.
- Side effects can include headaches and flushing.
There were no statistically significant differences between treatment groups in number or type of sexual problems or in number or percentage success of sexual attempts at baseline (Table 1).
What other information should I know?
A second Hamilton anxiety rating24 occurred at week 8. The clinical assessment of each patient and medical record was used to confirm DSM-IV–defined major depressive disorder in remission, substance-induced sexual dysfunction, and any exclusionary diagnoses. Serum blood samples drawn at baseline and at study end, before 11 AM on days 1 to 10 of the menstrual period (follicular phase), were stored at −80°C until assayed and measured following prescribed procedures (eg, chemiluminescent enzyme immunoassay, microparticle enzyme immunoassay, radioimmunoassay) at the Reproductive Endocrine Reference Laboratory at Massachusetts General Hospital, Boston. Full analysis procedures with lower limits of detection reported for assays performed at the Massachusetts General Hospital General Clinical Research Center core laboratory using commercially available kits are published by the manufacturer and available on request. Baseline demographics, safety, and tolerability evaluations were compared using descriptive statistics by χ2 and Fisher exact tests (when cell sizes were <5).
Addyi (filbanserin)
Independent samples t tests compared baseline patient characteristics and Clinical Global Impression sexual function scores between the study groups at end point. The χ2 analyses were used to evaluate group differences in categorical measures. Analyses were based on intent-to-treat with the last-observation-carried-forward analyses performed on all variables and included data from all protocol-treated patients. All randomized patients received and took at least 1 dose of study trial medication, had at least 1 efficacy assessment, and were included regardless of protocol deviations or whether they completed the study. The final analysis included women who completed the trial, but for the women who did not complete the trial, their baseline value was carried forward in separate analyses. The difference from baseline to end point in the mean (SD) change in the Clinical Global Impression scale sexual function improvement by intent-to-treat last-observation-carried-forward analyses (ie, lower ordinal score) was 4.8 (0.7) to 2.8 (1.0) with a difference of 1.91 (95%
Log in or create a free account to read this content
The 2 nonrandomized and untreated women did not differ on any demographic characteristics from those who entered the trial and were not included in the analyses. A total of 98 women were randomly assigned to receive active sildenafil (n = 49) or placebo (n = 49). The mean (SD) age of the women was 36.7 (7.1) years. They had been taking antidepressant medication for 27.7 (34.6) months. Distribution of prescribed antidepressants was comparable between groups. CI, 1.57-2.26) for the sildenafil group vs 4.7 (0.9) to 3.6 (0.9) with a difference of 1.10 (95% CI, 0.75-1.46)
| Drug Name | Mechanism | Approval Status | Cost per Dose | Common Side Effects |
|---|---|---|---|---|
| Sildenafil | PDE5 inhibitor | Not officially approved | $10-$20 | Headache, flushing |
| Tadalafil | Longer duration, PDE5 inhibitor | Limited use | $15-$30 | Muscle pain, headache |
| Vardenafil | Similar to sildenafil | Experimental | $12-$25 | Vision changes |
for the placebo group, which showed a significant difference of 0.8 (95% CI, 0.6-1.0, P = .001) between groups (Table 2).
| Strategy | Description | Notes |
|---|---|---|
| Low-dose initial | Starting with 25 mg, titrating up as needed | To minimize side effects |
| Maximum dose | Up to 100 mg, under medical supervision | To maximize effect, risk side effects |
| As-needed use | Taken before anticipated sexual activity | Short-term use |
| Daily use | Continuous daily dosing for sustained effect | Experimental, under doctor's guidance |